作者:Steven V. Ley、Miles N. Tackett、Matthew L. Maddess、James C. Anderson、Paul E. Brennan、Michael W. Cappi、Jag P. Heer、Céline Helgen、Masakuni Kori、Cyrille Kouklovsky、Stephen P. Marsden、Joanne Norman、David P. Osborn、María Á. Palomero、John B. J. Pavey、Catherine Pinel、Lesley A. Robinson、Jürgen Schnaubelt、James S. Scott、Christopher D. Spilling、Hidenori Watanabe、Kieron E. Wesson、Michael C. Willis
DOI:10.1002/chem.200801656
日期:2009.3.9
Rapamycin (1) is a macrocyclic natural product, established as a potent immunosuppressant and currently of interest to the scientific community as the framework for a series of novel anticancer drugs. Extensive studies have culminated in a new convergent total synthesis of 1, which features a number of group‐derived methodologies and an unusual catechol‐templating strategy for the construction of the
雷帕霉素(1)是一种大环天然产物,已被确立为有效的免疫抑制剂,目前作为一系列新型抗癌药物的框架引起了科学界的关注。广泛的研究最终得出了新的1的收敛全合成,该合成具有许多基于组的方法和一种异常的邻苯二酚模板化策略,用于构建具有挑战性的大环核。